By screening a Food and Drug Administration (FDA)-approved compounds library, clemizole has been identified as efficient to improve the epileptic phenotype resulting from Nav1.1 haploinsufficiency on a zebrafish model for Dravet syndrome (Baraban et al., 2013). This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.